-
Tetracycline C6589 for Reliable Cell Assays
2026-09-02
Learn how Tetracycline (SKU C6589) can support controlled microbiological selection and cleaner interpretation of cell-based viability or proliferation workflows. This scenario-based guide covers mechanism, DMSO compatibility, storage, controls, data interpretation, and practical vendor-selection criteria.
-
Vitamin Repurposing Against SARS-CoV-2: Docking Insights
2026-09-02
Eskandari’s 2022 study used molecular docking and molecular dynamics to evaluate vitamin-derived natural compounds against SARS-CoV-2 3CLpro and the spike receptor-binding domain. The work highlights a dual-target computational strategy for antiviral therapeutics research while showing why predicted binding must be followed by biochemical and cellular validation.
-
Acridine Orange hydrochloride Protocol Guide
2026-09-01
Acridine Orange hydrochloride provides differential fluorescent staining of double-helical and single-stranded nucleic acids for cytochemical workflows, including cell cycle analysis, apoptosis detection, and flow cytofluorometric nucleic acid staining. It is best used as a freshly prepared, validated staining reagent and is not appropriate for long-term solution storage or non-nucleic-acid targets without additional validation.
-
Hoechst 33342 for Hypoxia Vascular Cell Assays
2026-09-01
Hoechst 33342 turns live-cell nuclear labeling into a practical readout for endothelial cell and smooth muscle cell workflows under hypoxia. This guide connects chromatin visualization, cell counting, and nuclear morphology to the SP1/ADAM10/DRP1 study while emphasizing assay controls and troubleshooting.
-
Fluo-4 AM for Podocyte Calcium Assays
2026-08-31
Use Fluo-4 AM to convert rapid intracellular Ca²⁺ changes into actionable data in podocyte, receptor-trafficking, and diabetic nephropathy models. This workflow emphasizes live-cell kinetics, pathway-specific controls, and troubleshooting for reliable calcium signaling assays rather than fluorescence alone.
-
Viral RIPK3 Degradation Drives Inflammation
2026-08-31
Liu et al. identified a viral inducer of RIPK3 degradation, vIRD, that hijacks host SCF ubiquitin-ligase machinery to promote proteasomal destruction of a central necroptosis kinase. Using viral genetics, biochemical assays, and mouse models, the study shows that vIRD reshapes orthopoxvirus replication, inflammation, and mortality through RIPK3–MLKL-dependent pathways.
-
Protein A/G Magnetic Co-IP/IP Kit for Co-IP
2026-08-30
The Protein A/G Magnetic Co-IP/IP Kit streamlines endogenous protein-complex capture for interaction studies while also supporting antibody purification from biological fluids. Its magnetic workflow is especially useful for testing mechanistic relationships such as the RNF8–DAPK1 axis described in ischemic-stroke research.
-
Deracoxib Workflows for COX-2 Research
2026-08-29
Build a controlled inflammation assay around Deracoxib to separate COX-2-dependent prostaglandin responses from broader NF-κB activation. The workflow also supports translational pain studies and canine oncology experiments, including carefully titrated doxorubicin combinations.
-
Lenalidomide (CC-5013): Mechanism & Research Guide
2026-08-28
Lenalidomide, also called CC-5013, is an oral thalidomide derivative with immunomodulatory, anti-angiogenic, and direct antitumor activities. Evidence supports its use in multiple myeloma research and shows that DOT1L inhibition can potentiate lenalidomide responses in myeloma models.
-
Dabigatran for Mechanism-Resolved Coagulation Assays
2026-08-28
Dabigatran and Pradaxa are examined through an assay-centered framework that connects thrombin biochemistry with interpretable coagulation readouts. Learn how target selection, matrix effects, metabolite activity, and reversibility shape reliable anticoagulation research.
-
Balsalazide Prodrug Design in Active Ulcerative Colitis
2026-08-27
The reference review by Wiggins and Rajapakse presents balsalazide as a colon-targeted 5-aminosalicylate prodrug that uses bacterial azoreduction to release active 5-ASA in ulcerative colitis. Its principal clinical value is not a new inflammatory target, but improved local drug delivery, with evidence for effective and relatively rapid remission induction and a safety profile comparable to other oral 5-ASA agents.
-
Dabigatran etexilate: Assay Workflows
2026-08-27
Dabigatran etexilate supports activation-aware thrombin, plasma coagulation, platelet, and exposure–response studies. This workflow-focused guide shows how to prepare the compound, select meaningful endpoints, and troubleshoot prodrug conversion and matrix effects.
-
Intravesical p21 mRNA-LNPs for Bladder Cancer
2026-08-26
A 2026 FASEB Journal study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, inhibited tumor growth in an orthotopic mouse model, and limited systemic exposure, supporting localized mRNA delivery as a tumor suppressor replacement strategy.
-
Sodium Orthovanadate for Phosphorylation Assays
2026-08-26
Sodium Orthovanadate helps preserve labile tyrosine phosphorylation during cell lysis, western blotting, and protein tyrosine kinase assay development. This guide connects reversible phosphatase inhibition with adipocyte insulin-signaling workflows while addressing concentration selection, metabolic confounding, and assay recovery.
-
Pterostilbene Preserves Mitochondrial Quality in Fibroblasts
2026-08-25
Zhou et al. show that pterostilbene reduces senescence phenotypes in human dermal fibroblasts by improving mitochondrial quality, respiration, and mitophagy-associated clearance. The study connects mitochondrial remodeling with collagen preservation across cellular and UVB-induced mouse models, while also defining practical readouts for future dermal aging experiments.